Brian T. Herbst

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Nan Niu · 6 shared papers, 2021–2025 · strength 0.87
   • Paper Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancr… DOI 10.1186/s40364-024-00721-7↗
   • Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
   • Paper Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spect… DOI 10.1186/s13045-022-01373-6↗
2. Keyu Li · 6 shared papers, 2020–2025 · strength 0.80
   • Paper Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancr… DOI 10.1186/s40364-024-00721-7↗
   • Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
   • Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
3. Lei Zheng · 6 shared papers, 2020–2025 · strength 0.80
   • Paper Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancr… DOI 10.1186/s40364-024-00721-7↗
   • Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
   • Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
4. Alex B. Blair · 4 shared papers, 2020–2026 · strength 0.74
   • Paper CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models. DOI 10.1172/jci196622↗
   • Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
   • Paper Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ … DOI 10.20892/j.issn.2095-3941.2020.0273↗
5. Stephen T. Muth · 4 shared papers, 2020–2022 · strength 0.48
   • Paper Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spect… DOI 10.1186/s13045-022-01373-6↗
   • Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
   • Paper CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. DOI 10.1084/jem.20211631↗
6. Noah S Rozich · 3 shared papers, 2022–2024 · strength 0.40
   • Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
   • Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
   • Paper CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. DOI 10.1084/jem.20211631↗
7. Lei Zheng · 1 shared paper, 2026 · strength 0.39
   • Paper CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models. DOI 10.1172/jci196622↗
8. Elizabeth M. Jaffee · 1 shared paper, 2026 · strength 0.39
   • Paper CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models. DOI 10.1172/jci196622↗
9. Arsen Osipov · 3 shared papers, 2021–2024 · strength 0.39
   • Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
   • Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
   • Paper Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ … DOI 10.20892/j.issn.2095-3941.2020.0273↗
10. Mengni He · 2 shared papers, 2024–2025 · strength 0.37
    • Paper Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancr… DOI 10.1186/s40364-024-00721-7↗
    • Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
11. Kenji Fujiwara · 3 shared papers, 2020–2022 · strength 0.36
    • Paper Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spect… DOI 10.1186/s13045-022-01373-6↗
    • Paper CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. DOI 10.1084/jem.20211631↗
    • Paper Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibi… DOI 10.1136/jitc-2019-000351↗
12. Yao Xu · 3 shared papers, 2021–2022 · strength 0.34
    • Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
    • Paper CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. DOI 10.1084/jem.20211631↗
    • Paper Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ … DOI 10.20892/j.issn.2095-3941.2020.0273↗
13. Jun-Ke Wang · 2 shared papers, 2022–2025 · strength 0.33
    • Paper Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancr… DOI 10.1186/s40364-024-00721-7↗
    • Paper CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. DOI 10.1084/jem.20211631↗
14. Ding Ding · 3 shared papers, 2020–2022 · strength 0.31
    • Paper CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. DOI 10.1084/jem.20211631↗
    • Paper Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ … DOI 10.20892/j.issn.2095-3941.2020.0273↗
    • Paper Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibi… DOI 10.1136/jitc-2019-000351↗
15. Junke Wang · 2 shared papers, 2022–2024 · strength 0.28
    • Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
    • Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
16. Noelle R. Jurcak · 2 shared papers, 2020–2024 · strength 0.25
    • Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
    • Paper Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibi… DOI 10.1136/jitc-2019-000351↗
17. Christopher L. Wolfgang · 2 shared papers, 2021–2022 · strength 0.23
    • Paper Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humaniz… DOI 10.1016/j.canlet.2022.215722↗
    • Paper Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ … DOI 10.20892/j.issn.2095-3941.2020.0273↗
18. Sami Shoucair · 1 shared paper, 2025 · strength 0.21
    • Paper Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancr… DOI 10.1186/s40364-024-00721-7↗
19. Yiping Mou · 1 shared paper, 2025 · strength 0.21
    • Paper Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancr… DOI 10.1186/s40364-024-00721-7↗
20. May Tun Saung · 2 shared papers, 2020–2022 · strength 0.20
    • Paper CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. DOI 10.1084/jem.20211631↗
    • Paper Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibi… DOI 10.1136/jitc-2019-000351↗
21. Lei Zheng · 1 shared paper, 2019 · strength 0.20
    • Paper Precision medicine in pancreatic cancer: treating every patient as an exception. DOI 10.1016/s2468-1253(19)30175-x↗
22. Xu-Bao Liu · 1 shared paper, 2024 · strength 0.16
    • Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
23. Chunhui Yuan · 1 shared paper, 2024 · strength 0.16
    • Paper Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. DOI 10.1186/s13045-024-01576-z↗
24. Lei Zheng · 1 shared paper, 2022 · strength 0.16
    • Paper Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spect… DOI 10.1186/s13045-022-01373-6↗
25. Tengyi Zhang · 1 shared paper, 2022 · strength 0.16
    • Paper Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spect… DOI 10.1186/s13045-022-01373-6↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.